无症状PSA进展时从阿比特龙联合泼尼松转换为联合地塞米松的疗效
该单中心回顾性研究纳入48例转移性去势抵抗性前列腺癌(mCRPC)患者,在阿比特龙联合泼尼松治疗出现无症状生化进展后,将泼尼松转换为地塞米松继续联合阿比特龙。转换为地塞米松后的中位无进展生存期(PFS)为10.35个月,联合全程中位PFS为20.07个月,56.25%患者PSA下降或稳定。既往激素敏感时间长、转换时PSA低和AA+P治疗至PSA进展时间短与更长PFS相关。
要点
- 无症状PSA进展时从泼尼松转换为地塞米松是安全且低成本的策略。
- 转换后56.25%患者PSA下降或稳定,中位PFS为10.35个月。
- 激素敏感时间长、转换时PSA低和AA+P进展快提示更长PFS。
核心结论
- 在选择性mCRPC患者中,从泼尼松转换为地塞米松可获得对阿比特龙的长期应答且安全、不昂贵。
- 既往激素敏感时间长、转换时PSA水平低和AA+P治疗至PSA进展时间短的患者PFS更长。
研究设计与样本
- 单中心回顾性研究,纳入2013年1月至2016年4月接受阿比特龙治疗的93例患者中的48例连续无症状mCRPC患者。
- 患者在AA+泼尼松10 mg/日治疗出现生化进展后,转换为AA+地塞米松0.5 mg/日,直至影像学和/或临床进展。
- 主要终点为无进展生存期(PFS),并基于独立预后因素定义预后评分。
主要发现
- AA+P治疗的中位至PSA进展时间为8.94个月。
- AA+D治疗的中位PFS为10.35个月,AA+皮质激素(先P后D)的中位PFS为20.07个月。
- 56.25%的患者在转换后PSA水平下降或稳定。
- 单因素分析中,激素敏感持续时间长(≥5年;中位PFS 16.62 vs 4.17个月,HR 0.30,90%CI 0.16-0.56)、转换时PSA低(<50 ng/mL;中位PFS 15.21 vs 3.86个月,HR 0.33,90%CI 0.18-0.60)和AA+P治疗至PSA进展时间短(<6个月;中位PFS 28.02 vs 6.65个月,HR 0.41,90%CI 0.21-0.81)与更长PFS显著相关。
- 多因素分析中,激素敏感持续时间和PSA水平为独立预后因素。
关键数值与推荐
- 转换时激素敏感持续时间≥5年与中位PFS 16.62个月相关(对比4.17个月,HR 0.30,90%CI 0.16-0.56)。
- 转换时PSA<50 ng/mL与中位PFS 15.21个月相关(对比3.86个月,HR 0.33,90%CI 0.18-0.60)。
- AA+P治疗至PSA进展时间<6个月与中位PFS 28.02个月相关(对比6.65个月,HR 0.41,90%CI 0.21-0.81)。
临床怎么用
- 对于阿比特龙联合泼尼松治疗出现无症状PSA进展的mCRPC患者,可考虑转换为地塞米松联合阿比特龙。
- 转换决策可参考既往激素敏感持续时间、转换时PSA水平和AA+P治疗至PSA进展时间。
局限性
- 单中心回顾性研究,样本量有限(48例)。
- 研究未设对照组,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). MATERIALS AND METHODS: Among 93 patients treated with AA between January 2013 and April 2016 in our institution, 48 consecutive asymptomatic patients with mCRPC, who experienced biochemical progression on treatment with AA+P 10 mg/day, were included. A corticosteroid switch to AA+D 0.5 mg/day at PSA increase was administered until radiological and/or clinical progression. The primary endpoint was progression-free-survival (PFS). A prognostic score based on independent prognostic factors was defined. RESULTS: The median time to PSA progression on AA+P was 8.94 months. The median PFS on AA+D and AA+corticosteroids (P then D) was 10.35 and 20.07 months, respectively. A total of 56.25% of patients showed a decrease or stabilization in PSA levels after the switch. In univariate analysis, three markers of switch efficiency were significantly associated with a longer PFS: long hormone-sensitivity duration (≥5 years; median PFS 16.62 vs 4.17 months, hazard ratio [HR] 0.30, 90% confidence interval [CI] 0.16-0.56); low PSA level at the time of switch (<50 ng/mL; median PFS 15.21 vs 3.86 months, HR 0.33, 90% CI 0.18-0.60); and short time to PSA progression on AA+P (<6 months; median PFS 28.02 vs 6.65 months, HR 0.41 (90% CI 0.21-0.81). In multivariate analysis, hormone sensitivity duration and PSA level were independent prognostic factors. CONCLUSION: A steroid switch from P to D appears to be a safe and non-expensive way of obtaining long-term responses to AA in selected patients with mCRPC. A longer PFS has been observed in patients with previous long hormone sensitivity duration, and/or low PSA level and/or short time to PSA progression on AA+P.
引用
- Fenioux C, Louvet C, Charton E, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int. 2018. PMID: 30099821. doi:10.1111/bju.14511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。